Poznan University of Medical Sciences
Poznan, GreaterPoland, 61-848, Poland
Location status: Recruiting
NCT Number: NCT04879069
Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The Pulmonary Embolism Response Team (PERT) concept offers a rapid and multidisciplinary approach focused on improving outcomes for patients with PE. All institutionalized PERTs in Poland have been invited to join the study. The goal of this registry is to describe current practice and outcomes in patients with acute PE treated by Polish PERTs.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Poznan, GreaterPoland, 61-848, Poland
Location status: Recruiting
Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The presentation of PE may vary from asymptomatic or mild exertion disturbances (low-risk PE) treated with anticoagulants only to hemodynamic "obstructive" collapse and death (high-risk PE). Patient outcome depends on ability of the right ventricle to sustain the increased afterload caused by the embolic burden. Careful risk stratification is crucial, and the Pulmonary Embolism Response Team (PERT) concept offers a rapid and multidisciplinary approach focused on improving outcomes for patients with PE by advancing its recognition, diagnosis, and treatment. All institutionalized PERTs in Poland have been invited to join the study. The data is administrated by the Poznan University of Medical Sciences on the basis of an agreement between the PERT centres.
The goal of this registry is to describe current practice and outcomes in patients with acute PE guided by Polish PERTs. The primary data recorded include details of each patient's clinical status, co-morbidities, the administered treatment modalities, the results of additional studies (ab tests results, ECG, imaging studies), and the outcome.
The data collection will have no impact on the way the patient is diagnosed and treated.The study endpoints comprise respiratory failure, shock, death distal systemic embolization (i.e. stroke) and major or minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 hours after specific PE treatment implementation
Incidence of arterial blood saturation increase >92%
Time frame: 24 hours after specific PE treatment implementation
Rate of right ventricular strain reduction (right ventricle/left ventricle ratio assessment) in echocardiography
Time frame: Two weeks since PE diagnosis
Number of patients who died from pulmonary embolism (right heart failure)
Time frame: 3 months since PE diagnosis
Number of patients who died from pulmonary embolism (right heart failure)
Time frame: 3 months since PE diagnosis
Incidence of major bleedings assessed using ISTH criteria
Contact information is provided by the study sponsor or research team.
Poznan University of Medical Sciences
Other
Polish Multicenter Pulmonary Embolism Response Teams Outcomes Registry
Acronym: PolPERTs
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07491094
Cardiovascular Diseases, Clinical Deterioration
Gothenburg, Region Västra Götaland, Sweden
View Trial DetailsNCT06494878
Aspirin, Cardiovascular Diseases
Brussels, Belgium
View Trial DetailsNCT07350499
Arterial Thromboembolism, Cardiovascular Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT07213778
Cardiovascular Diseases, Embolism
La Mesa, California, United States
View Trial Details